Financial Results From Huhtamaki

28 October 1996

- Finnish company Huhtamaki had net sales from January to end-August 1996 of 5.15 billion markka ($1.1 billion), down 2% on the same period last year. Operating earnings were 379 million markka, up 23%, with a profit after financial items of 286 million markka, up 42%. Net income of 41 million markka was recorded, with earnings per share of 6.78 markka. Profits for the year are expected to be good since the sale of its pharmaceutical business Leiras was completed on September 2 (Marketletter September 9). Leiras had six-month sales of 561 million markka.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight